Kronos Bio Inc is a biotechnology business based in the US. Kronos Bio Inc shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Kronos Bio Inc employs 96 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Kronos Bio Inc
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KRON – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Kronos Bio Inc stock price (NASDAQ: KRON)
Use our graph to track the performance of KRON stocks over time.Kronos Bio Inc shares at a glance
Latest market close | $3.74 |
---|---|
52-week range | $2.96 - $25.76 |
50-day moving average | $4.25 |
200-day moving average | $10.93 |
Wall St. target price | $22.25 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.92 |
Buy Kronos Bio Inc shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kronos Bio Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kronos Bio Inc price performance over time
Historical closes compared with the close of $3.74 from 2022-06-29
1 week (2022-06-23) | 4.47% |
---|---|
1 month (2022-06-01) | 8.41% |
3 months (2022-04-01) | -49.12% |
6 months (2021-12-31) | -72.48% |
1 year (2021-07-01) | -84.63% |
---|---|
2 years (2020-06-27) | N/A |
3 years (2019-06-27) | N/A |
5 years (2017-06-27) | N/A |
Kronos Bio Inc financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -23.66% |
Return on equity TTM | -42.31% |
Profit margin | 0% |
Book value | $5.66 |
Market capitalisation | $203.1 million |
TTM: trailing 12 months
Kronos Bio Inc share dividends
We're not expecting Kronos Bio Inc to pay a dividend over the next 12 months.
Have Kronos Bio Inc's shares ever split?
Kronos Bio Inc's shares were split on a 3:2 basis on 2 November 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Kronos Bio Inc shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Kronos Bio Inc shares which in turn could have impacted Kronos Bio Inc's share price.
Kronos Bio Inc overview
Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio Inc in the news
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
Kronos Bio Announces Participation in Upcoming Investor Conferences
Frequently asked questions
What percentage of Kronos Bio Inc is owned by insiders or institutions?Currently 15.545% of Kronos Bio Inc shares are held by insiders and 66.587% by institutions. How many people work for Kronos Bio Inc?
Latest data suggests 96 work at Kronos Bio Inc. When does the fiscal year end for Kronos Bio Inc?
Kronos Bio Inc's fiscal year ends in December. Where is Kronos Bio Inc based?
Kronos Bio Inc's address is: 1300 South El Camino Real, San Mateo, CA, United States, 94402 What is Kronos Bio Inc's ISIN number?
Kronos Bio Inc's international securities identification number is: US50107A1043 What is Kronos Bio Inc's CUSIP number?
Kronos Bio Inc's Committee on Uniform Securities Identification Procedures number is: 501052104
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert